Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q3 2022 Earnings Call Transcript

Page 3 of 3

So we need to focus on making more of those kinds of products that can help hard to treat populations. And so that’s why we’ve spent. We’ve had some pretty good advisors helping us identify not only, of course, the U.S. patents, but the foreign patents that you need, that your bigger companies typically want to be interest in a license for the technology. They’ve got to have those foreign components too. And so that’s why we’ve been spending time developing those.

Laura Engel: Right. Well, great progress and again, I appreciate you taking my call, and I’ll get back in the queue. Thank you, Peter.

Peter Nielsen: Thank you. Thank you. And this concludes the question-and-answer session. I would like to turn the call over to Peter Nielsen for any closing comments.

Peter Nielsen: Thank you again everyone for joining us and for your continued support of Bio-Path Holdings. Have a great day. Bye now.

Operator: Thank you. The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect your lines.

Follow Bio-Path Holdings Inc. (NASDAQ:BPTH)

Page 3 of 3